339450 Results

Show all   Save search   Copy query
Sort   by:  
 Page size 
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (CAR-T Metabolites)
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14640 | MetaboLights
MetabolomicsMetabolic Dynamics of In Vitro CD8+ T Cell Activation

CD8+ T cells detect and kill virally infected or cancerous cells. When activated from their naïve state, T cells undergo a complex transition, including major metabolic reprogramming. Detailed resolution of metabolic dynamics of a wide range of metabolites is needed to advance the field of immuno...

2021-06-02 | MTBLS2145 | MetaboLights
MetabolomicsExtracellular-acidosis restricts one-carbon metabolism and preserves T cell stemness
The accumulation of acidic metabolic waste products within the tumor microenvironment profoundly inhibits effector functions of tumor-infiltrating lymphocytes (TILs). However, it is unclear whether extracellular-acidosis impacts T cell metabolic fitness and differentiation status. Here, we surprisin...
2023-01-17 | MTBLS6661 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14634 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (Glucose Tracer)
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14641 | MetaboLights
MetabolomicsIdentification of AK4 and RHOC as novel oncogenes addicted by adult T-cell leukemia
Adult T-cell leukemia (ATL) is a highly aggressive T-cell malignancy characterized by human T-cell leukemia virus type 1 (HTLV-1) infection. ATL has a very poor prognosis and lacks satisfactory treatments; therefore, it is critical to identify novel targets in ATL cells in order to develop effective...
2025-02-03 | MTBLS11858 | MetaboLights
MetabolomicsNanoinducers-mediated Mitochondria-Selective Degradation Enhance T Cell Immunotherapy Against Multiple Cancers

Cancer immunotherapy utilizing cytotoxic T lymphocytes (CTLs) has demonstrated significant promise in clinical applications, but cancer immunosuppressive mechanisms hamper further progress in T cell immunotherapy. Here we show a correlation between cancer cell mitochondria content and their resis...

2025-03-13 | MTBLS12284 | MetaboLights
MetabolomicsA comprehensive metabonomic and transcriptomic analysis reveals how inhibiting glycolysis affects regulatory T cell proliferation

Background: Blocking glycolysis inhibits regulatory T cells (Tregs), which are often hijacked by tumor cells whose survival relies on glycolysis to inhibit antitumor immunity. However, how glycolysis influences Treg proliferation/differentiation remains unclear. Monocarboxylate transporters (MCTs...

2024-08-06 | MTBLS8002 | MetaboLights
MetabolomicsA polyamine-centric blood-based metabolite panel predictive of poor response to CAR T-cell therapy in large B cell lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (r/r) large B-cell lymphoma (LBCL) results in durable response in only a subset of patients. MYC overexpression in LBCL tumors is associated with poor response to treatment. We tested whether a MYC-driven polyamin...

2022-10-31 | MTBLS5381 | MetaboLights
MetabolomicsButyrate epigenetically licenses sustained epithelial-T cell crosstalk for intestinal immune tolerance

Butyrate, one of the most abundant microbial-derived metabolites in the gut, is important in regulating intestinal homeostasis. In this study, we used untargeted global metabolomics to landscape the intestinal epithelial cellular metabolites changed by butyrate treatment.

2026-06-26 | MTBLS14301 | MetaboLights
Sort   by:  
 Page size